Pattern of failure in anaplastic glioma patients with an IDH1/2 mutation
| Autor: | A. Newey, Edward C. Hsiao, Matthew Wong, Mustafa Khasraw, Marina Kastelan, Chris Brown, Michael Back, Dasantha Jayamanne, Helen Wheeler, Dale L. Bailey, David Brazier, Geoff Schembri |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male Oncology medicine.medical_specialty Multivariate analysis IDH1 medicine.medical_treatment DNA Mutational Analysis Oligodendroglioma Astrocytoma Anaplastic glioma 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine Risk Factors Internal medicine Temozolomide medicine Humans Radiology Nuclear Medicine and imaging Treatment Failure Patterns of failure Brain Neoplasms business.industry Middle Aged medicine.disease Combined Modality Therapy Isocitrate Dehydrogenase Survival Rate Radiation therapy Isocitrate dehydrogenase Positron-Emission Tomography 030220 oncology & carcinogenesis Female Radiotherapy Intensity-Modulated Neoplasm Recurrence Local business Follow-Up Studies medicine.drug |
| Zdroj: | Strahlentherapie und Onkologie. 196:31-39 |
| ISSN: | 1439-099X 0179-7158 |
| DOI: | 10.1007/s00066-019-01467-0 |
| Popis: | The current study aimed to assess patterns of failure (PoF) in anaplastic glioma (AG) patients managed with intensity-modulated radiation therapy (IMRT) and their relationship to molecular subtype. The outcomes of AG patients managed between 2008 and 2014 and entered into a prospective database were assessed, including PoF. AG was initially defined using the WHO 2007 classification, but for analysis, patients were subsequently recategorised based on WHO 2016 as anaplastic oligodendroglioma (AOD), astrocytoma isocitrate dehydrogenase (IDH) mutant (AAmut) or astrocytoma IDH wildtype (AAwt). Management involved IMRT and temozolomide (TMZ), including from 2011 patients with an IDH mutation (IDHmut) planned with 18F-fluoroethyltyrosine (FET) and 18F-fluorodeoxyglucose (FDG) positron-emission tomography (PET). PoF was local, marginal or distant in relation to the IMRT volume. Relapse-free survival (RFS) was calculated from the start of IMRT. A total of 156 patients were assessed, with median follow-up of 5.1 years. Of these patients, 75% were IDHmut, 44% were managed at first or later relapse and 73% received TMZ. Relapse occurred in 68 patients, with 6‑year RFS of 75.0, 48.8 and 2.5% for AOD, AAmut and AAwt, respectively (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink